STOCK TITAN

CRNX (NASDAQ: CRNX) insider sells shares via 10b5-1 and option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CRNX: Notice of proposed and recent insider sales of Common Stock

The filing lists proposed transactions and recent dispositions by an insider. It shows a proposed exercise of stock options to sell 15,000 shares03/18/2026 and proposed settlement of 9,756 Restricted Stock Units03/15/2026. The filing also discloses three 10b5-1 sales of 5,000 shares each01/02/2026, 02/02/2026, and 03/02/2026 with proceeds of $232,590.50, $247,485.50, and $202,234.00, respectively.

Positive

  • None.

Negative

  • None.

Insights

Insider executed option exercise and reported planned share transfers plus routine 10b5-1 sales.

The filing documents a planned 15,000-share03/18/2026 and settlement of 9,756 RSUs03/15/2026. It also lists three completed 10b5-1 dispositions of 5,000 shares each on 01/02/2026, 02/02/2026, and 03/02/2026 with reported proceeds.

These entries are consistent with compensation-related liquidity events and pre-arranged trading; cash-flow treatment is tied to the insider's exercises and plan sales. Subsequent filings may disclose net shares retained post-transactions.

Transactions show use of a 10b5-1 plan and standard issuer settlement mechanics.

The disclosure names 10b5-1 sales01/02/2026, 02/02/2026, and 03/02/2026. The planned option exercise and RSU settlement are listed as issuer-related events on their stated dates.

Regulatory filings accompanying these actions should show final settlement and any tax-withholding; review subsequent reports for confirmation of executed sale volumes and net proceeds.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What shares did CRNX report proposing to sell?

The filing shows a proposed exercise-and-sale of 15,000 common shares03/18/2026 and settlement of 9,756 RSUs03/15/2026. These entries are listed under the securities to be sold.

What 10b5-1 sales by CRNX insider are disclosed?

Three 10b5-1 sales are reported: 5,000 shares01/02/2026, 02/02/2026, and 03/02/2026. Reported proceeds were $232,590.50, $247,485.50, and $202,234.00, respectively.

Who is identified as the selling party in the disclosed sales?

The 10b5-1 sales are attributed to an individual listed as Dana Pizzuti

Do the filings state how proceeds will be used by CRNX?

The filing does not attribute proceeds to the issuer; the entries reflect insider liquidity events and issuer settlement of RSUs and options. Specific use-of-proceeds language for the company is not included in the excerpt.
Crinetics Pharmaceuticals

NASDAQ:CRNX

View CRNX Stock Overview

CRNX Rankings

CRNX Latest News

CRNX Latest SEC Filings

CRNX Stock Data

3.90B
101.58M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO